FDA Licenses the First Freeze-Dried Plasma for the US

Q: What did FDA approve?

A Biologics License Application (BLA) for Ezplaz Freeze Dried Plasma (FDP), granted to Vascular Solutions, LLC, a subsidiary of Teleflex, on 29 July 2026. FDA describes it as the first freeze-dried plasma product licensed for use in the United States.

Q: What makes it different from conventional plasma?

Conventional plasma must be stored frozen and thawed before use. Ezplaz stores at room temperature, remains stable through temperature fluctuations, and reconstitutes in about a minute. It ships in a plastic bag rather than a glass bottle, reducing breakage risk in transport and handling.

Q: Who is it approved for?

Adult patients who need plasma and for whom other plasma products are not available — including bleeding patients, patients requiring massive transfusion, and certain patients experiencing bleeding while on warfarin. It is supplied in Group AB and Group A with low-titer anti-B blood types, chosen to reduce risk when a patient's blood type is not yet known.

Q: Why did the Defense Department help fund this?

Freeze-dried plasma was among the first products identified under Public Law 115-92, enacted in December 2017, which set up a Department of Defense–FDA collaboration to expedite development and review of products addressing serious or life-threatening conditions facing U.S. military personnel. FDA expects Ezplaz's room-temperature stability and rapid reconstitution to suit austere environments, potentially including combat zones, remote areas, and disaster response.

FDA licensed the first freeze-dried plasma product for use in the United States on 29 July 2026, granting a Biologics License Application from Vascular Solutions, LLC, a Teleflex subsidiary, for Ezplaz Freeze Dried Plasma. The product's defining feature is what it does not need: a freezer. Conventional plasma has to be stored frozen and thawed before transfusion; Ezplaz stores at room temperature and reconstitutes in about a minute, a difference with consequences well beyond the hospital blood bank.

In brief

FDA licensed Ezplaz Freeze Dried Plasma on 29 July 2026, granting the BLA to Vascular Solutions, LLC, a subsidiary of Teleflex — FDA's first-ever U.S. license for a freeze-dried plasma product.
It stores at room temperature, tolerates temperature fluctuations, and reconstitutes in about a minute, packaged in a plastic bag rather than glass to cut breakage risk.
Approved for adults needing plasma when other plasma products are unavailable: bleeding patients, patients needing massive transfusion, and certain bleeding patients on warfarin. Supplied in Group AB and Group A low-titer anti-B types.
Developed in part under Public Law 115-92 (2017), a Defense Department–FDA program to expedite products for U.S. military medicine; FDA expects use in austere and combat environments.

What the license actually covers

Ezplaz is indicated for transfusion in adult patients who need plasma and for whom other plasma products are not readily available — a category that includes bleeding patients, patients requiring massive transfusion, and certain patients experiencing bleeding while being treated with warfarin. It is supplied in Group AB and Group A with low-titer anti-B blood types, a choice aimed at emergency use before a patient's own blood type has been confirmed: those types carry a lower risk of adverse reaction if given to a patient of unknown type under time pressure. The product reconstitutes from its freeze-dried form in roughly a minute, a fraction of the time conventional frozen plasma takes to thaw.

Why the packaging is part of the story

Two engineering choices do most of the work here. First, room-temperature stability removes the cold chain that conventional plasma depends on end to end — freezer storage, careful thawing, and use within a narrow post-thaw window. Second, Ezplaz ships in a plastic bag rather than a glass bottle, which FDA and Teleflex both note reduces the risk of breakage during handling and transport. Neither change alters what plasma does clinically; both change where it can go and who can carry it. A product that survives temperature swings and doesn't need a freezer travels into settings — ambulances, rural clinics, forward medical units — that frozen plasma logistically cannot reach in a usable state.

A military-medicine pathway, now a civilian product

Freeze-dried plasma was among the first products named under Public Law 115-92, signed in December 2017, which built a formal Department of Defense–FDA collaboration to speed the development and review of products addressing serious or life-threatening conditions facing American military personnel. FDA has said it expects Ezplaz's stability profile to suit austere environments, potentially including combat zones, remote areas, and disaster response — the settings the 2017 law was written for. The license itself, though, is a standard civilian BLA: Ezplaz is now available for use in any U.S. transfusion setting where FDA's approved indication applies, not restricted to military or emergency use. It is the kind of dual-track outcome that a Defense–FDA product-development partnership is designed to produce — a capability built for the battlefield, licensed for the blood bank.

Frequently asked questions

What did FDA approve?

A BLA for Ezplaz Freeze Dried Plasma, granted to Vascular Solutions, LLC (a Teleflex subsidiary) on 29 July 2026 — the first freeze-dried plasma product licensed for use in the United States.

What makes it different from conventional plasma?

It stores at room temperature instead of frozen, tolerates temperature fluctuations, reconstitutes in about a minute, and ships in a plastic bag rather than a glass bottle to reduce breakage risk.

Who is it approved for?

Adults needing plasma when other plasma products are unavailable — bleeding patients, patients needing massive transfusion, and certain bleeding patients on warfarin. Supplied in Group AB and Group A low-titer anti-B types.

Why did the Defense Department help fund this?

Freeze-dried plasma was named under Public Law 115-92 (2017), a DoD–FDA program to expedite products for military medicine. FDA expects Ezplaz's stability to suit austere and combat environments.

Sources & further reading

FDA, “FDA Licenses First-Ever Freeze-Dried Plasma Product in the U.S.,” press announcement, 29 July 2026. fda.gov
FDA, Biologics License Application approval letter for Ezplaz Freeze Dried Plasma, 29 July 2026. fda.gov
Teleflex Incorporated, “Teleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma,” 29 July 2026. teleflex.com

Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.